TriangleCARLOTTA01 (NCT05836896)
CARLOTTA01 trial for Neoplasms (NCT05836896). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Multiple myeloma comes back, again and again, until the standard drug classes are exhausted. CAR T cells aimed at BCMA, a marker on myeloma cells, are approved and effective, but relapses follow.
The idea: an academic BCMA CAR T, built with a tighter grip on its target.
At the University Hospital in Dresden, a patient's own T cells receive a high-affinity receptor for BCMA, designed to bind the marker more firmly than earlier constructs. After conditioning chemotherapy, the cells are returned in a single infusion, at one of four rising dose levels.
CARLOTTA-01 is a first safety study, for myeloma after at least two prior lines and for some relapsed large B-cell lymphomas. Martin Wermke leads it. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.